I have received media credentials to attend and cover the 2025 BIO CEO and Investors Conference, February 10-11 in New York City. I will be on hand, and if you are interested in live, independent coverage, I need charge no expenses.
Thanks for your consideration, and Happy Holidays.
One article I am proposing as coverage from this conference has to do with bone marrow transplants for breast cancer. This therapy (along with high dose chemotherapy) was considered experimental when I was in law school, and was the subject of bitter litigation.
So fast-forward to the present, and what happened? Survival rates for breast cancer have increased markedly, especially with those women who have genetically-driven forms of the disease. Is the gain in survival associated with more use of bone marrow transplants for breast cancer?
No. High dose chemotherapy with bone marrow transplant is not routinely used for patients with breast cancer; instead, the benefit has come about partially because the biopharma industry has developed several targeted therapies addressing genetically-associated forms of the disease.
Is it possible that the managed care companies were right?
